Unquoted Biotechs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Unquoted Biotechs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: nigel bates	11/30/2005 8:34:20 AM
	of 253

UK biotech PIramed signs $230 mln Genentech deal LONDON, Nov 30 (Reuters) - Privately owned British biotech company PIramed Ltd said on Wednesday it had signed a deal potentially worth up to $230 million with Genentech Inc. for the development of a new class of cancer drugs. The collaboration with the U.S. biotechnology giant is one of the largest pre-clinical deals ever signed by a UK biotech company. The experimental drugs discovered by PIramed target PI 3-kinase, an enzyme involved in a large number of cancers. Under the agreement, PIramed will receive an upfront payment and may receive milestone payments up to a potential total of around $230 million, depending on how the compounds work in clinical tests. PIramed, which is based in Slough, west of London, is backed by venture capital group Merlin Biosciences and JP Morgan Partners...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next